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Salivarian trypanosomes are single cell extracellular parasites that cause infections in
a wide range of hosts. Most pathogenic infections worldwide are caused by one of
four major species of trypanosomes including (i) Trypanosoma brucei and the human
infective subspecies T. b. gambiense and T. b. rhodesiense, (ii) Trypanosoma evansi and
T. equiperdum, (iii) Trypanosoma congolense and (iv) Trypanosoma vivax. Infections with
these parasites are marked by excessive immune dysfunction and immunopathology,
both related to prolonged inflammatory host immune responses. Here we review the
classification and global distribution of these parasites, highlight the adaptation of human
infective trypanosomes that allow them to survive innate defense molecules unique
to man, gorilla, and baboon serum and refer to the discovery of sexual reproduction
of trypanosomes in the tsetse vector. With respect to the immunology of mammalian
host-parasite interactions, the review highlights recent findings with respect to the B cell
destruction capacity of trypanosomes and the role of T cells in the governance of infection
control. Understanding infection-associated dysfunction and regulation of both these
immune compartments is crucial to explain the continued failures of anti-trypanosome
vaccine developments as well as the lack of any field-applicable vaccine based
anti-trypanosomosis intervention strategy. Finally, the link between infection-associated
inflammation and trypanosomosis induced anemia is covered in the context of both
livestock and human infections.
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INTRODUCTION
Human African Trypanosomosis and Animal African Trypanosomosis are two well-known
diseases that affect sub-Saharan Africa and have historically prevented the development of vast
lands of the African continent into highly productive agricultural areas. However, the first salivarian
pathogenic trypanosome to be discovered was T. evansi, a parasite identified by Dr. Griffith Evans
in 1880, in horses and camels suffering from a disease called Surra on the Indian subcontinent
(1). Almost 140 years after this initial discovery, a wealth of world-wide epidemiological data
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on pathogenic trypanosomes shows they are present on four
different continents. Molecular parasite mechanisms, that allow
the escape from the hosts’ immune and non-immune defense
systems, have been discovered and various interactions in the
context of vector biology have been described. However, in
the end the data available today has still not given us a way
to intervene in trypanosomosis transmission by means of an
effective anti-parasite vaccination strategy. Hence, control still
relies on a combination of active case diagnosis and treatment,
as well as vector control (2, 3). In this review we cover the
classification of trypanosomes, which has recently become under
scrutiny (4), as well as new discoveries with respect to genetic
exchange between trypanosomes that takes place in the insect
vector (5, 6). In addition, the paper provides an update on
recent discoveries with respect to the B cell destructive potential
of trypanosomes (7, 8), T cell biology (9), and the impact
of trypanosomosis on red blood cell (RBC) homeostasis and
infection-associated anemia (10). Throughout the data review,
both animal trypanosomosis (AT) and human trypanosomosis
(HT) have been considered. However, as most recent data shows,
this “artificial” distinction might be less useful than previously
thought, as atypical human trypanosomosis (a-HT), which can
be caused by various animal trypanosomes, is now gaining more
and more attention in the field (11).
SETTING THE SCENE FOR SALIVARIAN
TRYPANOSOMOSIS
Trypanosomes are unicellular protozoan organisms of the class
Kinetoplastida that cause a wide range of infections in a broad
range of hosts. The latter includes not just mammals but also
fish (12), birds (13), and reptiles (14), while insect vectors
actually should be considered not just as transmission “tools”
but also as definite hosts. Indeed, it is only here that sexual
reproduction stages have been reported, as comprehensively
outlined in a recent review by Gibson W. (5). In mammals,
both salivarian and stercorarian trypanosomes cause diseases that
affect the health status of the infected host in multiple ways.
While the stercorarian trypanosomes are an important group
of parasites, the main focus of this review is directed toward
the pathogenic salivarian trypanosomes that cause infections
in human, livestock, and game animals. These infections are
marked by the extracellular nature of the infecting agent, causing
pathologies and health complications that are very different
from the features that characterize intracellular pathogenic
infections such as those caused by the stercorarian T. cruzi
parasite. An additional complication that arises when describing
trypanosomosis, is the use of the term African Trypanosomosis.
This denomination is very often used in an incorrect way. Indeed,
as will be described in this review, all major pathogenic salivarian
trypanosome infections do occur on the African continent.
However several of the pathogens responsible for these diseases
have moved “out of Africa” and infections are progressing
throughout the world. A last introductory remark for this paper
is the fact that Human African Trypanosomosis or HAT has
recently been brought under control in a very significant manner
by huge consorted international efforts of the last decennium
(15). Hence, this might give the impression that trypanosomosis
has become a disease of the past. This however could very well
be a wrong assumption for three main reasons. First, there are
no reports that suggest that AT is near to being controlled on
a world-wide scale. Second, the most aggressive form of HAT
caused by T. b. rhodesiense has a zoonotic origin, so as long as
human infective trypanosomes are present in a wildlife reservoir,
re-emergence of the disease remains a risk (16, 17). This holds
true even if the majority of infections caused by T. b gambiense
are being brought under control. Third, reports of a-HT in-
and outside Africa show that “African” trypanosomosis is only
part of the problem (11). Hence, for now trypanosome diseases
still remain a threat to human health and to agriculture systems
of emerging economies. In the absence of any vaccine strategy
preventing the spread of these infections, continued research into
host-parasite interactions is needed. This will provide a better
understanding of trypanosome diseases itself, the mechanisms of
disease resistance, modes of immune evasion, and ultimately the
reasons for continued failure of vaccination attempts.
CLASSIFICATION OF THE MAIN
PATHOGENIC SALIVARIAN
TRYPANOSOMES
Trypanosomes belong to the sub-kingdom Protozoa, the
order Kinetoplastida, the family Trypanosomatidae, and genus
Trypanosoma. The large numbers of different species belonging
to this genus have been classified in several subgenera according
to their morphology. For the salivarian pathogenic trypanosomes
the subgenera include Trypanozoon, Duttonella, Nannomonas,
and Pycnomonas, of which the first three account for the vast
majority of human and animal infections and are the subject of
this review. Their combined geographic spread covers most of
the developing world (Figure 1).
The first trypanosome subgenus, Trypanozoon, is composed
of several Trypanosoma species, which are human and animal
infective and includes the first pathogenic trypanosome ever to
be discovered i.e. Trypanosoma evansi. Today, T. evansi is a
parasite that is considered to havemainly a veterinary importance
(1), causing the disease Surra in a wide range of economically
important mammals such as horses, cattle, goats, buffalos, dogs,
and camels. In addition, the parasite can be found in game
animals such as deer, wild pigs, and capybaras, representing a
reservoir that often might escape attention. Today, T. evansi
is found across Central and South America, North Africa,
the Russian territories, the Indian subcontinent, China, and
Southeast Asia (23). Transmission mainly occurs mechanically
through the bite of bloodsucking insects from the family
Tabanidae (genus Tabanus) (24), Chrysops (25), Atylotus (26),
and Muscidae (genus Stomoxys and Haematobia) (18). It is this
mechanical transmission that has allowed the parasite to move
beyond the tsetse fly region and out of Africa. Morphologically,
T. evansi has long been considered as a monomorphic parasite
with the main bloodstream form appearing as so called “long
slender” forms. However, the appearance of short intermediate
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FIGURE 1 | Geographic distribution of salivarian trypanosomosis. Salivarian trypanosomosis is a worldwide problem caused in large by Trypanosoma evansi,
Trypanosoma brucei (including the human infective subspecies T. b. gambiense and T. b. rhodesiense), Trypanosoma vivax and Trypanosoma congolense. T. brucei,
and T. congolense infections are limited to the sub-Saharan tsetse belt. In contrast, as T. vivax and T. evansi can be mechanically transmitted, these parasites have
migrate beyond the tsetse belt, out of Africa and into South America and Asia [adapted from (18–22)].
forms has also been reported, but only in blood smears of
infected cat and monkey (27). Important is that the parasite
has a peculiar kinetoplast, characterized by either a reduced
(lack of maxi-circles and homogenous mini-circles) or a total
absence of kinetoplast DNA (kDNA) (28). This deficiency is
thought to lock T. evansi in the bloodstream form, as they
are unable to transcribe the kDNA genes required to perform
the oxidative phosphorylation required for the developmental
processes in the midgut of the tsetse (29). For long, this altered
kDNA characteristic has been used to differentiate T. evansi from
African T. brucei subspecies. Recently however, genetic analysis
of a large battery of both T. evansi and T. brucei parasites has
shown that the situation is more complex, and that many T.
evansi parasites are closely related to T. brucei, even more closely
than the relation between T. evansi parasites from different
geographic locations (30–32). In addition, these data suggest that
T. evansi arose multiple times from a different T. brucei ancestor.
Hence, this has sparked a debate about the nomenclature of the
Trypanozoon parasites. While it has been suggested by some to
considerT. evansi as aT. brucei variant, amost recent revision has
been proposed based on the proper application of the principles
of biological nomenclature. This proposal suggests to rename all
T. brucei subspecies as T. evansi subspecies, and even adopt the
use of T. evansi gambiense and T. evansi rhodesiense for human
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infective African Trypanosomes (4). Important in the context of
the parasite-host interplay of T. evansi is the notion that several
human T. evansi infections have been reported in- and outside
Africa (11). However, despite the wide geographic distribution of
T. evansi, the reports on human non-African trypanosomosis are
overall extremely rare. However, it cannot be excluded that one of
the reasons for the scarce amount of data on a-HT is simply due
to the lack of proper diagnostic practices that are able to correctly
identify human trypanosomosis in T. evansi endemic areas.
The second Trypanozoon subspecies to be discovered was T.
brucei, endemic to sub-Saharan Africa and transmitted by biting
flies of the genus Glossina, commonly known as tsetse, with
tsetse meaning “fly” in the Tswana language of Southern Africa.
T. brucei parasites present a major health problem for humans,
as the causative agent of the disease called HAT, or sleeping
sickness. Domestic animals such as cattle, pigs, small ruminants,
and game animals are also common hosts for T. brucei, in
which the latter serve as a natural reservoir of the parasite.
Three morphological indistinguishable subspecies of T. brucei
are known (namely T. b. gambiense, T. b. rhodesiense, and T. b.
brucei.) with T. b. gambiense and T. b. rhodesiense responsible for
human trypanosome diseases in West/Central and East Africa,
respectively. Uganda is one of the only countries where the
two forms of HAT appear in adjacent regions. T. b. brucei, on
the other hand, is unable to infect humans and is responsible
for animal trypanosomosis only. The correct identification of
the T. brucei subspecies is nearly impossible when solely based
on their morphology or geographical origin. Indeed, all three
subspecies appear as pleomorphic bloodstream parasites, having
both long slender and short stumpy forms. However, molecular
approaches have shown that this group is highly heterogeneous
(33). The exclusive presence of the serum resistance associated
(SRA) gene in T. b. rhodesiense has been used as a marker for the
identification of this subspecies (34, 35). T. b. gambiense specific
identification can be done through PCR amplification of the T.
b. gambiense-specific glycoprotein (TgsGP) gene that encodes for
a receptor-like glycoprotein, which is also involved in normal
human serum resistance (36).
The third species within the subgenera of Trypanozoon,
responsible for livestock infections, is Trypanosoma equiperdum.
This parasite can be sexually transmitted amongst species from
the family Equidae (horses and donkey), causing a venereal
disease known as Dourine. Due to this transmission mode, the
parasite has also acquired a wide geographic distribution. As for
T. evansi, to which it is very closely related, also the classification
of T. equiperdum as a separate species has been under scrutiny for
many years (37), and several authors have suggested that there is
no scientific argument tomake a species level distinction between
the two.
The second trypanosome subgenus responsible for salivarian
trypanosomosis is Dutonella, which is mainly composed of two
species, i.e., T. vivax and T. uniforme. Due to the global socio-
economic impact caused by T. vivax infections in domestic
animals, most of the studies of this subgenus have been carried
out on this particular parasite species. This trypanosome is a
pathogenic parasite species mainly found in Africa and South
America (38). So far, only a single human infection has ever been
reported (11). In Africa, transmission occurs in large through the
bite of tsetse flies, having the highest infection rate of any tsetse-
transmitted trypanosome species (39, 40). This high infectivity
could be attributed to the relatively simple cycle of development
in the vector’s mouthparts. The transmission beyond Africa is
mainly carried out mechanically by hematophagous flies from
the genus Stomoxys and Tabanus, which transmit the disease
to domestic animals such as cattle and goats, as well as to
endemic wild animals such as capybaras, deer, and bubaline
antelopes. Despite its large economic impact, especially in South
America,T. vivax remains one of the less studied animal-infective
Trypanosoma species. The main issue with T. vivax in the context
of experimental parasitology and immunology research is the
fact that virtually no parasites of this species are capable to be
grown inmice. Hence, virtually all laboratory infections inmouse
models (incl. Tv700, STIB 719, STIB 731-A, ILRAD 560, IL 1392)
are being executed with the derivatives of Y468T. vivax clone that
was originally isolated in Nigeria that happened to “grow well” in
mice after extensive adaptation (41). Hence, it remains to be seen
if the TvY486 T. vivax reference strain is a good representative
parasite for the general population of parasites found both in
Africa and South America regarding host-parasite interaction
mechanisms.
The third subgenus of pathogenic salivarian trypanosomes
is Nannomonas, encompassing three species of animal-infective
trypanosomes, i.e., Trypanosoma simiae, Trypanosoma godfreyi,
and Trypanosoma congolense. The two first species are mainly
infective to mammals belonging to the Suidae family (domestic
pigs, warthogs etc.) while T. congolense has a broader range
of hosts including livestock and game animals, but is generally
accepted to be non-infective to humans. It should however be
mentioned that a mixed T. b. gambiense/T. congolense infection
has been reported in a human (42) and that in vitro testing
of human serum-induced trypanolysis has shown a resistance
phenotype in several stocks (43). T. congolense is the major tsetse
transmitted pathogenic salivarian livestock trypanosome present
in sub-Saharan Africa and causes large economical losses in
the countries where it is endemic. The disease caused by this
parasite is referred to as Nagana, meaning depressed spirit in
the Zulu language of Southern Africa. During transmission, T.
congolense develops in the midgut and proboscis of the tsetse
vector. Mechanical transmission can occur, involving mainly
Tabanus and Stomoxys species (44). In general, T. congolense
is considered to be a monomorphic parasite. The host-parasite
interaction as well as immunopathology associated with T.
congolense infections has been better studied than in the case of
T. evansi and T. vivax. However, it is important to point out the
fact that while the molecular parasite surface structure has been
well-described and compared to T. brucei (45), the regulation and
kinetics of surface coat variation, as well as the infection of the
coat with the immune system have never been analyzed in detail.
Hence, most statements about these interactions and regulations
are based on the assumption that T. congolense should behave
the same way as T. brucei. A second scientific issue that plagues
the T. congolense research literature is the fact that it is often
used as a “chronic” model in comparison to “acute” T. brucei
infections. This artifact originates from the fact that a specific
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chronic T. congolense clone, i.e., Tc13, has been used in major
immunological investigations for almost three decades (46). In
contrast, the vast majority of experimental host-parasite research
in T. brucei brucei and T. brucei rhodesiense models has been
done with much more virulent T. b. AnTat 1 or LouTat 1 clones
(47–49). While these studies by themselves all resulted in valid
experimental data, it should be said that there are virulent T.
congolense strains, resulting in infections in mice which display
very similar survival times as the T. brucei clones mentioned
above (50). Unfortunately, these more virulent T. congolense
isolates have not been systematically used in comparative studies
with T. brucei. Hence, reports that compare highly virulent T.
brucei infections with low virulent T. congolense infections, and
subsequently provide conclusion in which infection outcome is
linked to the species-specific background of the parasite, should
be taken with utmost caution. Of note is that the high genetic
heterogeneity of T. congolense has led to the division of this
parasite in three different subgroups i.e., Savannah, Kilifi, and
Forest within the same species (51).
GENERAL LIFE CYCLE OF SALIVARIAN
TRYPANOSOMES AND INTERACTION
WITH BOTH INSECT AND MAMMALIAN
HOSTS
The life cycle of cyclically transmitted salivarian trypanosomes
inside their vector shows the plasticity of those parasites to
adapt to new environments (Figure 2). Today, most of the
knowledge on parasite transmission comes from the T. brucei
model in which infection of tsetse flies occurs when the non-
dividing short stumpy bloodstream form parasites are taken
up during a fly’s blood meal, reaching the fly’s midgut and
transforming into procyclic trypomastigotes (52). Once the
parasite infection is established in the fly’s midgut, the parasites
migrate anteriorly to the proventriculus of the fly. Here,
elongated trypomastigotes start to divide asymmetrically into
both long and short epimastigotes of which the latter migrate
toward the salivary glands and attach to the epithelial cells of the
gland. Next, a final division occurs giving rise to the host-infective
metacyclic forms. Once in the host’s bloodstream, metacyclic
parasites transform into long slender shaped bloodstream form
parasites, which further divide by binary fission and represent
the active dividing parasite form during themammalian infection
stage. It is at this stage that trypanosomes express the Variant
Surface Glycoprotein (VSG) (55). This coat protein is encoded by
a battery of over 1,000 different genes, mosaics and pseudogenes
(56) and serves as an antibody decoy defense system (57). Indeed,
VSGs are highly immunogenic and induce VSG-specific antibody
responses. Hence, by regularly altering VSG variant expression,
the parasite avoids efficient immune recognition and destruction
(58). Genetic regulation of antigenic variation has been studied
in detail and has been shown to involve various mechanisms of
DNA recombination and transcription regulation of VSG genes
(59, 60). With respect to mechanisms of genetic variation in
trypanosomes, there is now ample evidence supporting the fact
that T. brucei parasite mating or sexual reproduction does take
place in the tsetse (5, 6). Hence, while the tsetse is conventionally
referred as the insect vector for trypanosomosis, it should actually
be considered as the definite host for the parasite. To put it
in other words: mammals are merely the vessel that is used to
ensure that trypanosomes are able to migrate from one tsetse
to the next, and in addition provide long-term reservoirs that
allow trypanosomes to survive seasonal periods in which fly
populations are diminished. Sexual reproduction inside the insect
vector offers the parasite in theory the chance of generating new
hybrids, combining different parental characteristics. Important
to note however is the fact that the effectiveness of trypanosome
infection in the fly rapidly decreases with the age of the fly, hence
also affecting the chance to generate hybrid descendants. Using
both green and red fluorescent trypanosomes to study hybrid
formation, it was shown that midgut and salivary gland infection
rates were highest when flies were exposed to parasites in their
first feed (53). Waiting 21/2 weeks for a first parasite exposure
reduced the infection success by half. Interestingly, exposing
tsetse flies to two different trypanosome lines in a consecutive
feeding experiment resulted most often in the establishment of
the first infection only, as if the primary infection was able
to push the vector to mount a protective immune response
preventing secondary infection. Under natural circumstances,
this would greatly reduce the chance of hybrids being formed,
although the experimental conditions used above showed that
in all combinations tested, hybrid formation did take place
(53). As will be outlined later in this review, even the rarest
hybrid formation events can have a significant impact on the
transition from AAT to HAT, as it allows generation of a
continuous pool of new human infective T. rhodesiense parasite
strains (54). With respect to the vector immunity mentioned
above, several studies published in the recent past have made
contributions to the understanding of the mechanism underlying
tsetse anti-trypanosome immunity. It is interesting to note that
tsetse immunity development per se requires the presence of
the obligate symbiont Wigglesworthia in the larval stage of the
fly, transmitted through maternal milk gland secretion (61, 62).
This finding complements the notion that the development of
a fully functional innate immune system of the mature adult
tsetse fly depends on the establishment of a bacterial microbiome
population, and that the immaturity of the immune system is
responsible for the high susceptibility to trypanosome infections
during a first blood feeding (63). The fly immunity itself relies on
multiple mechanisms. Indeed, the action of scavenger receptor
peptidoglycan-recognition protein LB (PGRP-LP) is crucial for
the colonization of the fly by its Wigglesworthia symbiont, and
in addition has a direct trypanocidal activity on both procyclic
and bloodstream form trypanosomes (64, 65). In addition, anti-
trypanosome immunity relies on activation of the immune
deficiency regulated pathway and antimicrobial peptides (66, 67),
as well as reactive oxygen species (ROS) mediated defenses (68),
which provides combined protective immunity at the level of
the midgut and hemocoel. Interesting here is that for some
time the peritrophic matrix, which is a chitinous protective
layer lining the insect gut, has been considered as a physical
barrier that could provide protection against invading infections.
However, RNA interference-based reversed genetic approaches
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have shown that the matrix is a true immunological regulator.
Its integrity is necessary to build a proper immune context in
the defense against different microbes, including trypanosomes,
through its role in the expression of the antimicrobial peptide
attacin as well as dual oxidase and iNOS, both involved in the
production of reactive oxygen intermediates (ROIs) (65). Finally,
the tsetse fly’s specific TsetseEP protein was shown to provide
anti-trypanosome protection at the level of the midgut (69).
Interestingly, starvation of flies reduces immune responsiveness
and increases susceptibility toward trypanosome infections both
in young and older flies (70–72).
Naturally, from a human and economic point of view, it is
the mammalian infection stage that has attracted most attention
in the past. It is only more recently that the parasite-vector
interaction and biology has received more detailed attention and
that also non-T. brucei infections have been studied in tsetse
(73, 74). These reports show that in fact both T. congolense and
T. vivax are much more effective in establishing tsetse infections
than T. brucei. In particular, for T. congolense it has been shown
that this parasite is particularly effective in reaching the proboscis
of the fly, where the trypomastigote-epimastigote transformation
takes place. In this case, migration from the foregut to the
mouthparts appeared to occur with high efficiency. In contrast,
T. brucei is much less efficient in colonizing the tsetse, as most
parasites do not survive the migration from the foregut to the
salivary glands. Investigating both T. brucei and T. congolense
infections in parallel have suggested that T. brucei adopted to
final survival in the salivary gland, as this niche would not be
preoccupied by the much more efficiently growing T. congolense
parasites. Hence, despite the fact that both parasites use the
same transmission vector, and that also for T. congolensemeiotic
reproduction has been reported in the teste vector (75), there
are remarkable differences in the way the two trypanosomes
infect and occupy the body of the insect host. In recent years,
specific attention has also been given to the immunological
events that take place at the bite site of the tsetse, in order to
explain how successful mammalian infections are initiated. Here,
it has become clear that there is a crucial role for tsetse saliva
components in preventing local blood clothing, vasodilation, and
neutrophil influx, all leading to the successful establishment of
a primary infection and allowing metacyclic saliva parasites to
be transformed successfully into long slender bloodstream form
parasites (76, 77).
Besides the biological vector transmission described above,
mechanical transmission is a second way of ensuring parasites
can move from one mammalian host to the next. This mode
has been described for T. congolense, T. evansi, and T. vivax,
but only the latter two have successfully used this way of
transmission to migrate out of Africa, into other continents. The
main vectors that have been reported today for both trypanosome
species are the horsefly, stable fly, horn fly, and deerfly. In all
cases, mechanical transmission occurs when a fly with blood-
contaminated mouthparts, containing living bloodstream form
parasites, rapidly changes feeding hosts allowing the parasites to
be transmitted without any intermediate insect-specific forms. To
date, virtually no information is available on possible immune
interactions that could make this way of parasite transmission
more or less successful. Interestingly, also nothing is known
about the immune events that aid in parasite transfer back
to the fly. Indeed, it is remarkable that livestock parasitaemia
levels are often extremely low, presenting blood parasite load
levels that are hardly detectable by microscopy. Yet, even when
circulating parasite numbers are extremely low, flies still manages
to successfully pick up parasites while taking very small blood
meal volumes. Whether this is due to the fact that parasitaemia
in the skin microvasculature is uniquely high as compared to the
general blood circulation, or whether fly saliva has unique and
potent trypanosome chemoattractant, remains to be elucidated.
HUMAN TRYPANOSOMOSIS IN AFRICA IS
ONLY PART OF THE PROBLEM
In 2009, the number of reported HAT cases dropped below
10.000 for the first time in 50 years, and the most recent figures
available for 2015 indicate that the global incidence of HAT
has dropped below 3.000. It is now estimated that by 2020
HAT will no longer be considered as a major human health
problem in Africa and hence will also no longer be listed as
a neglected disease (78). With HAT being caused by either
Trypanosoma brucei gambiense (>97%) or Trypanosoma brucei
rhodesiense (<3%) (79), these numbers and assumptions are
mainly based on the current West/Central African situation.
Considering however that T. b. rhodesiense is a zoonotic parasite
with a cattle and wildlife reservoir, re-emergence of HAT is going
to remain a crucial concern in Africa. Indeed, whether or not the
reservoir of T. b rhodesiense has been brought under control is
hard to verify due to the insufficient systemic reporting on T.
b. rhodesiense game and cattle infections. In addition, beyond
the borders of the African continent the existence of non-T.
brucei human trypanosomosis could become a future problem
as T. evansi infections spread around the globe. Despite the
reports of T. evansi infections in humans (80–83), this parasite
is still not widely considered as a human pathogen. The lack
of interest in these infections, combined with the continued
spread of these trypanosomes mainly in South America, the
Indian subcontinent, and Asia, risks of exposing humans to a new
type of “unconventional” disease that will require a whole new
approach to trypanosomosis world-wide. In addition, the lack
of experimental studies on T. evansi infections as compared to
T. brucei infections makes it harder to link the discussion about
the genetic classification of T. evansi as a T. brucei subspecies
to data dealing with the cellular and molecular mechanisms that
govern host-pathogen interactions, pathology development, and
zoonotic behavior.
Taken the importance of the zoonotic aspect of most
remaining human trypanosome infections, it is clear that
(African) Animal Trypanosomosis (AAT) per se deserves
particular attention. In fact, there is a wealth of information
available with respect to geographic distribution of AAT, immune
pathologies including anemia and vaccine efforts as well as
failures. These reports outnumber the scientific data published
on host-pathogen aspect of human trypanosomosis. However,
this contrasts very much the situation with respect to the actual
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FIGURE 2 | Cyclic transmission of salivarian trypanosomes mediated by tsetse and other biting flies. Most lifecycle data of African Trypanosomes is based on the T.
brucei cycle involving the tsetse (52). Here, short stumpy form parasite are taken up by the fly, progress through the body of the insect vector passing via the midgut,
proventiculus and salivary gland, to be re-injected though the proboscis as infective metacyclic trypomastigotes into a new target. In the bloodstream, differentiation to
long slender forms occurs followed by binary fission proliferation. Differentiation back to short stumpy forms will complete the cycle. While T. congolense and T. vivax
can follow a similar cyclic transmission mode, the latter also is known to be spread through mechanical transmission (53, 54), as is the case for T. evansi (1). T.
equiperdum spreads through sexual transmission only (37). Sexual reproduction of trypanosomes itself has been reported to take part in the teste, and has been
reported for both T. brucei and T. congolense (5).
understanding of trypanosome diseases. Indeed, while many
have focused on experimental models to understand human
trypanosomosis in the past, much less effort has been made
to understand the fundamentals of animal trypanosomosis. A
fine example to illustrate this is the issue of antigenic variation.
For more than four decades, scientists have been studying
antigenic variation of the VSG coat used by trypanosomes
to deliver a protective response against the host antibody
defense system. All work that included genetic approaches as
well as molecular biology approaches combined with computer
modeling, has been done for T. brucei, largely ignoring the fact
that the main cattle parasites i.e., T. congolense and T. vivax
are very different trypanosomes that might use other systems of
regulation and defense. For example, comparative studies of the
VSG repertoire conducted in T. congolense and T. vivax indicated
that the scale of the VSG recombination differs between two
species, being more frequent in T. congolense than in T. vivax.
Moreover, T. vivax populations were shown to be consistent
with clonal reproduction (84), while the T. congolense ability to
undergo sexual reproduction generates opportunities for allelic
recombination among VSG genes (85). Hence, to date we are
left with molecular tools that are very suitable to study a wide
range of host-parasite interactions in mice which could model
human infections, but at the same time we have very little
experimental models and tools to study AT. One striking example
is T. equiperdum, which is hardly studied in comparison to other
infections due to the fact that it causes a disease characterized
by sexual transmission in horses, a feature so far not reported
in mice. In fact, only a single report is available on experimental
sexual transmission of trypanosomosis in mice, and this report
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is dealing with T. b. gambiense (86). However, whether sexual
transmission of T. brucei gambiense is a real issue in human
trypanosomosis, remains a matter of debate (87) and more
species-specific research is needed to resolve these issues.
ADAPTATIONS OF ANIMAL INFECTIVE
TRYPANOSOMES TO HUMAN HOST
Humans are considered naturally resistant to pathogenic animal
trypanosomes such as T. b. brucei, T. evansi, T. equiperdum, T.
congolense, and T. vivax. The mechanism of human resistance
to those trypanosomes is based on the presence of cytolytic
factors in the high density lipoprotein (HDL) fraction of normal
human serum (NHS) (88) and is attributed to two fractions called
trypanosome lytic factor 1 and 2 (TLF1 and TLF2), with the latter
being the major active compound (89). The human infective T.
brucei subspecies T. b. gambiense and T. b. rhodesiense are known
to be resistant to TLF lysis through various mechanisms. A
number of reports demonstrating T. evansi infections in humans
has triggered a new wave of interest in molecular mechanisms
underlying human infectivity in the context of the transition
from an animal infective trypanosome to a zoonotic pathogen
causing disease in humans. While TLF1 and TLF2 have slightly
different compositions, they both contain the haptoglobin related
protein (HPR) and Apolipoprotein L1 (ApoL1), of which the
latter is considered themain active lytic compound. Furthermore,
TLF2 is complexed with IgM molecules and has a much higher
molecular mass than TLF1, but is lipid poor (90). With respect
to the mechanisms of lysis and resistance to NHS, initial data
was obtained in an experimental model for T. b. rhodesiense.
Here, it was shown that resistant and susceptible sub-clones can
be derived from a common ancestor by passaging trypanosomes
in either the presence or absence of human serum. This work
gave rise to the discovery of the SRA gene, encoding a truncated
VSG and located within the VSG expression site (91). Transfer
of the gene to T. b. brucei showed that the presence of this
single gene indeed was enough to confer resistance to NHS
(92). Subsequently, the identity of SRA allowed to characterize
ApoL1 as the active serum compound (93) that acts through
both lysosomal and mitochondrial membrane permeabilization
(94). The inhibitory mechanism of SRA was shown to rely on
its capacity to block the membrane pore-forming capacity of
ApoL1 upon entering the acid compartments of the lysosomal
system (95–98). Finally, the haptoglobin-hemoglobin receptor
(HpHbR), localized in the flagellar pocket, was identified as
the trypanosome receptor involved in TLF1 uptake (99), while
the mechanism for TLF2 uptake has still not been elucidated
(100). Indeed, HpHbR knock down T. b. brucei parasites remain
sensitive to both NHS and TLF2 lysis (101). However, as both
TLFs contain the same active ApoL1 compound, the SRA is
capable of blocking all NHS activity. Interestingly, the SRA gene
is only present in T. b. rhodesiense and hence has been used in
a string of different diagnostic approaches for HAT, including
PCR and LAMP, targeting not just human samples but also
livestock and game reservoirs as well as the tsetse vector, in
various regions in Eastern Africa. Of note is a report in which
a Ugandan HAT survey indicated that 20% of parasitologicaly
confirmed T. b. rhodesiense cases resulted from infections that
could not be detected by any of the SRA PCR methods described
so far. Whether this indicates that SRA-negative human infective
T. b. rhodesiense parasites exist, implying these parasites have
alternative NHS resistance mechanisms, or whether the negative
results were due to SRA gene polymorphism that prevented PCR
primer annealing, remains amatter of debate (102). The existence
of such SRA gene polymorphisms has been studied in the context
of human disease severity (54). Most recently, using SRA as a
genetic tracer, it has been shown that genetic recombination
between T. b rhodesiense and the much larger pool of T. b. brucei
animal trypanosomes allows for the continuous generation of
new SRA-positive human infective parasites (103, 104). This once
again indicates that in order to really bring HAT under control,
AAT and particularly the animal T. b. rhodesiense reservoir has to
be eliminated as well.
Interestingly, more than 97% of all human trypanosomosis
infections are caused by SRA-negative T. b. gambiense (79),
a parasite that is subdivided in Group 1 and Group 2 T. b.
gambiense (105). While Group 1 parasites have an invariant
phenotype toward NHS resistance, Group 2 parasites show a
variable degree of resistance, modulated by the actual exposure to
NHS. Neither Group 1, nor Group 2 parasites have the SRA gene
(8), indicating that there are multiple ways to mount resistance
to NHS. Literature of the last 5 years has mainly focused on
the Group 1 T. b. gambiense resistance, showing that these
parasites have acquired a combination of defense systems which
allows them to resist the lytic action of NHS. This includes
a specific point mutation in the HpHbR in combination with
reduced receptor expression, reducing TLF1 uptake (106, 107).
However, as this receptor is not a main player in TLF2 uptake,
T. b. gambiense needs additional mechanisms to survive in
human blood. These involve the alteration of lipid membrane
fluidity by the T. b. gambiense-specific glycoprotein (TgsGP)
(108, 109), as well as increased cysteine protease activity in
the digestive vacuoles of the parasite. The latter is believed to
directly affect ApoL1 activity (110). Today, it remains unclear
how T. b. gambiense Group 2 parasites deal with the toxicity of
NHS.
T. evansi parasites express neither SRA, nor TgsGP, but now
have been reported in several instances as human pathogens
causing a-HT (11, 18, 80, 82, 111). Similarly to T. b. rhodesiense
and T. b. gambiense Group 2 parasites, a remarkable phenotypic
plasticity of T. evansi has been described upon exposure to
NHS, with resistance occurring after prolonged NHS exposure
and being absent when NHS selective pressure is removed.
Screenings of various T. evansi isolates indicated that some
even display natural resistance to NHS, while others were found
to be fully sensitive (112). In line with these observations in
T. evansi, even T. b. brucei NHS resistance has now been
reported. In the latter, a switch to a resistant phenotype
was recorded to occur upon repetitive exposure to NHS or
TLF1 in the absence of the SRA gene (113). However, a
fragment homolog to SRA, named SRA basic copy (SRAbc),
was found in the T. brucei brucei TREU927/4 strain, which
exhibits low resistance to NHS (114). Similarly, one of the
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human infective T. evansi isolates was shown to contain the
SRAbc homolog (115). Interestingly, the T. b. brucei parasites
exhibiting increased NHS resistance had a significant reduction
in TLF1 uptake, which coincided with downregulation of T.
b. brucei HpHbR mRNA levels (100). Hence, it seems that
the resistance mechanism in these parasites shows a mixed
but attenuated phenotype of those found in either T. b.
gambiense or T. b. rhodesiense, as if the latter could have been
selected as “optimized” derivatives of T. b. brucei semi-resistant
predecessors.
With respect to human T. evansi, it is important to highlight
that at least one human infective case has been attributed
to the lack of functional ApoL1 (81). Indeed, a frameshift
mutation, found in both ApoL1 alleles of the patient, resulted
in the ability of trypanosomes to establish infection and to
survive in the human bloodstream. This strongly suggests that
human trypanosome resistance in large relies on a non-classical
immune mechanism, i.e., lipid membrane disruption by TLF.
However, a Vietnamese a-HT T. evansi victim was shown to
have fully functional ApoL1 alleles and a normal concentration
of serum ApoL1 (116). Hence, this shows that there is an
additional role for the immune system in the overall defense
against trypanosomes, most likely involving a combination of
the action of antibodies, cytokines, and complement factors.
In at least two confirmed human T. evansi infections, the
infected individuals were shown to have a compromised immune
system. One case relates to a pregnant woman from Mumbai,
India suffering from HIV/AIDS, anemia, and upper respiratory
tract infection (117). The second case relates to the above
mentioned Vietnamese woman who had just given birth (116),
with pregnancy itself being known as a unique immune condition
that is modulated by fetus development resulting in immune
alterations that in some cases in facilitation of parasite growth.
Important is that also in experimental T. evansi infections in
mice, in particular IgM antibodies are crucial for parasitaemia
control (118). This indicates that when “natural resistance” such
as the resistance conferred by ApoL1 fails, the antibody-mediated
immune response does provide a second defense barrier against
the progressing of infection.
Finally, it should also be mentioned that several reports
in the past have indicated the existence of a-HT caused by
the stercorarian T. lewisi parasite (119). Here, resistance to
NHS lysis was correlated with resistance to human ApoL1 as
well. Hence, it seems that while multiple mechanisms have
been acquired by various trypanosomes to block the lysosomal
pore-forming catalytic activity of NHS, this activity itself is
executed in large by a single factor, i.e., ApoL1. This finding
itself has attracted scientific attention over the last years
with respect to primate evolution (120), and has resulted in
the findings that (i) ApoL1 is the common lytic factor in
human, gorilla, and baboon primate sera (7, 8, 121), (ii) the
chimpanzee, orangutan, and macaque, which are susceptible
to all T. brucei subspecies, lack functional ApoL1 (121), and
(iii) the baboon ApoL1 variant is capable of killing even T.
b. gambiense and T. b. rhodesiense, as opposed to the human
ApoL1 (122, 123). The latter finding has prompted an attempt
to generate genetically modified TLF transgenic livestock that
would be able to resist all known pathogenic trypanosome species
(122).
THE ROLE OF B CELLS AND ANTIBODIES
IN SALIVARIAN TRYPANOSOMOSIS
As outlined above, VSG switching and antigenic variation,
including the generation of VSG mosaic genes, have generally
be considered as the major defense systems that parasites
have developed against the host’s adaptive immune system (56,
124, 125). However, in recent years it has become clear that
trypanosomes have developed several precautionary adaptations
that provide a rescue in case they do get recognized by
antibodies. The reason for this is obvious: even if different
VSG variants exhibit different hypervariable loops, and even
if mosaic VSG present new epitopes to the immune system,
there is no reason to assume that the overall pool of infection-
induced antibodies is not at all capable of detecting new
parasite variants. In fact, the existence of the cross-reactive
nature of anti-VSG antibodies has been used since the beginning
of trypanosome immunology research. Here, the VSG of the
first arising variant or living cloned parasites, expressing a
single VSG, have been used to monitor fluctuating anti-VSG
titers throughout infection for weeks or months (57, 126).
More interestingly maybe is the fact that reinfection models
have shown that weeks into a primary infection, mice can
be killed by a secondary infection with virulent trypanosomes
expressing exactly the same VSG as the primary infection
(127). In order to understand these results, three major host-
parasite interactions mechanisms have to be considered. First,
trypanosomes have developed a very efficient way of driving
endocytosis. This system allows to continuously clear surface
bound antibodies from the VSG coat, preventing antibody-
mediated lysis (128). Secondly, while antibody/complement-
mediated lysis has long been proposed to result in antibody-
mediated trypanosome killing, it is important to note that
AKR mice, which are natural C5 complement knockout mice,
are able to clear peaks of parasitaemia in a similar way as
other mice. This shows that the lack of complement-mediated
lysis does not prevent the immune system of controlling peak
stage parasite levels (129). Third, there is now ample evidence
that trypanosomes cause a B cell depletion pathology, which
is initiated by the very rapid disappearance of immature B
cells in the bone marrow, as well as transitional and IgM+
marginal zone B cells from the spleen, followed by a gradual
depletion of Follicular B cells (FoB) (127, 130). This has
now been reported for T. b. gambiense and T. congolense
infections (50, 131). Mechanisms involved in the depletion
process have been linked to IFNγ-mediated inflammation (132),
NK-mediated B cell destruction (133), and direct cell-cell
contact-mediated B cell apoptosis (111, 127). Once FoB cell
depletion is accomplished by the parasite, it becomes impossible
for the host to generate new efficient antibody responses
against newly arising VSG variants (Figure 3). In addition, it
hampers anti-VSG memory recall responses against previously
encountered variants, hence making the host susceptible to
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secondary infections with old variants. This might also explain
the accumulation of mosaic VSG variants during later stages
of infection (56). Indeed, the question whether later variants
are immunologically distinct (or not) from their ancestral
variants, which has so far not been answered, might not be
important at all. Possibly, these variants arise simply from
the continuous gene rearrangements that are ongoing at the
telemoric ends of the VSG expression sites and are tolerated,
due to the lack of antibody-mediated elimination by the host,
rather than being produced in order to evade the already existing
antibodies.
B cell dysfunction, associated to trypanosomosis, also has
a secondary detrimental effect on the mammalian host, i.e.,
the elimination of vaccine-induced memory recall responses.
Indeed, in an experimental model for DTPa vaccination, it was
shown that T. b. brucei is capable of destroying immunological
memory rendering vaccinated mice susceptible to infections
with Bordetella pertussis (130). This was not a result of an
infection-associated immunosuppression, as it persisted after
anti-trypanosome drug treatment and the elimination of active
trypanosome infections. This detrimental effect of trypanosomes
on non-related vaccine efficacy has also been reported in
other models and natural infections. Although not thoroughly
studied in human infections, one study has shown that antibody
titers induced by the anti-measles vaccine are significantly
downregulated in HAT patients, and that curative HAT treatment
did not result in a restauration of antibody titers (Figure 4). For
obvious ethical reasons, this study stopped short of assessing
whether or not the remaining titers would still confer protection.
In addition, the study did not address the question whether
vaccine-induced memory recall responses were affected (138).
With respect to AT, more data is available in particular with
respect to T. evansi and T. congolense infections. Indeed,
such infections in pigs were shown to abrogate protective
immune responses generated against the classical swine fever
vaccine (139). They were characterized by significantly reduced
antibody responses, leukopenia, and high fever. Similarly, T.
evansi infections in water buffalos, vaccinated against Pasteurella
multocida (hemorrhagic septicemia), showed impaired capacity
to mount a humoral and cell-mediated immune response
upon challenge (140). When cattle, harboring T. congolense
and T. vivax, were given a Brucella abortus vaccine or
were vaccinated against contagious bovine pleuropneumonia,
specific antibody responses to the vaccine were shown to
be severely depressed (135, 141–143). Similarly, T. congolense
infected goats vaccinated with Bacillus anthracis showed a
profoundly diminished anti-anthrax antibody responses (144),
while T. congolense infected cattle were shown to suffer from
immunosuppression and failed recall responses in a foot-and-
mouth vaccination setting (145). Taken together, these studies,
conducted in natural hosts for animal trypanosomes such
as cattle, water buffalos, goats, and pigs, confirmed studies
in mice showing that trypanosome infection induces severe
impairment of B cell responses and antibody production to
a number of non-trypanosome related commercial veterinary
vaccines.
THE ROLE OF T CELLS AND T
CELL-DERIVED CYTOKINES IN
SALIVARIAN TRYPANOSOMOSIS
Taken the extracellular nature of salivarian trypanosome
infections, initial thoughts on the control of infection were
naturally focused on the role of antibodies and B cells. However,
already early in the 1980’s it became obvious that while the
virulence of experimental trypanosomosis was not linked to the
expression of a specific VSG variant, or the use of a specific
MHC-II type, CD4+ T cells played an absolutely crucial role
in infection control (146). Twenty-five years after this initial
discovery, it was shown that major T cell responses against
cryptic T cell epitopes play a major role in trypanosomosis
control (147, 148). This observation caused a major paradigm
shift in the way trypanosomosis control is thought to occur, as
it shows that T cell help is not just needed to support effective
B cell functioning and antibody production, but that it plays a
crucial second B cell-independent role during the progression
of infection. This role of T cell biology might initially have
been underestimated, as a multitude of studies had shown that
trypanosomosis, both inmice and cattle, results in the occurrence
of T cell immunosuppression (49, 149). However, these reports
mostly referred to suppression of T cell proliferation and not to
cytokine secretion. To date, the active disease controlling role of
T cells is mainly attributed to the cytokine production in which
polarization toward a Th1-type response is crucial for initial
parasitaemia control (137). Detailed analysis of both T. brucei
and T. congolense infections has indeed shown that early IFNγ
production is crucial for the control of the onset of infection
(Figure 3). This hypothesis was initially driven by the description
of the cytokine production profile of CD4+T cells, and was later
corroborated by the use of neutralizing anti-IFNγ antibodies
as well as the use of IFNγ knockout mice (150, 151). The
latter were shown to have an impaired control of the first peak
of parasitaemia, followed by their inability to clear increasing
parasite numbers, leading to the early death of the mice using the
C57Bl/6 model (152). In experimental T. congolense infections,
it was demonstrated that while hyper-susceptible BALB/c mice
preferentially mount an infection associated Th2-type response
against the Tc13 T. congolense parasite, Th1-biased C57Bl/6 mice
were able to survive for up to 6 months when infected with
the same clone (136). Also here it was shown that altering
immune balances, by treatment with neutralizing anti-cytokine
(or cytokine receptor) monoclonal antibodies, drastically alters
the outcome of infection (153). Most recently, it was reported
for T. brucei that the CD4+ IFNγ response is preceded by the
production of this cytokine by NK and NKT cells, followed by a
marked upregulation of IFNγ production by CD8+ T cells (154).
This was observed in both the spleen and the liver of infected
mice. However, by 10 days post infection it was clear that these
cell populations were either drastically reduced in numbers or
became totally depleted, leaving the CD4+ T cells to execute
the major task of cytokine production. A comprehensive report
on the overall role of IFNγ in various trypanosome infection
models was recently published by Wu et al. (155). Interestingly,
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FIGURE 3 | Antigenic variation and host immune destruction are closely linked. Antigenic variation of the trypanosome VSG surface coat enables trypanosomes to
escape specific antibody-mediated destruction, resulting in immunologicaly distinct parasites occurring at regular intervals (upper panel). To prevent total eradication,
trypanosomes undermine the immune system by ablation of the B cell compartment. In mice, this results in abrogation of an efficient antibody mediated immune
defense system, allowing different parasite variants to occur simultaneously (schematically represented as the week 3 situation). Despite to co-occurrence of several
variants, later-stage parasitaemia peaks usually have a reduced magnitude in terms of actual parasite numbers as various non-B cell defense systems aid in
parasiteamia control [upper panel, adapted from (134)]. The lower panel schematically represent the finding that onset of infection is followed by a rapid depletion of
the MZ B cell compartment (purple), followed by a gradual destruction of the FoB cell compartment (red) (116, 119). While the initially host immune response
generates effector Plasma B cells, later waves of newly arising parasite variants fail to be efficiently depleted due to the impaired capacity of the host to deliver a
renewed Plasma B cell response (green). Overall immunopathology is initiated by excessive production of IFNγ during the first week of infection, involving mainly
CD8+ T cells, NK cells, and NKT cells. By 7 days post infection, IFNγ production is taken over by CD4+ T cells, while activated macrophages now produce excessive
amounts of TNF that contribute to pathology (135, 136). Later-on in infection, production of IL-10 has been documented to counteract the initial inflammation (137).
to date only one single trypanosome factor has been identified
as being able to induce IFNγ production by T cells, CD8+ T
cells in particular. This molecule, named TLTF (trypanosome
lymphocyte triggering factor) (10) has been characterized in T.
brucei and T. evansi parasites (156), but a homolog has not been
described for other trypanosomes. TLTF was shown to be capable
of inducing IFNγ production by astrocytes, suggesting a direct
role of the molecule in the pathology development of sleeping
sickness (157). This hypothesis has been further supported by
the finding that IFNγ deficient mice show reduced CD4+ and
CD8+ T cell influx into the brain parenchyma of T. brucei
infected mice (158). Important is that when the role of T cells
and IFNγ are considered within a trypanosomosis context, IL-
10 was shown to be the main counter regulator of infection-
associated inflammation in both T. brucei and T. congolense
models. The source of the latter was proposed to be the regulatory
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FIGURE 4 | Trypanosomosis-induced B cell destruction results in prolonged B cell dysfunction. Experimental infections in mice have shown that trypanosomes can
destroy non-related DTPa induced vaccine responses (upper panel). Vaccinated mice that have been confronted with trypanosomes fail to clear diphtheria bacteria
from their lungs, even when the bacterial challenge is performed after the trypanosome infection has been cleared by drug treatment [adapted from (119)]. Indeed is
was shown that while the commercial vaccine Boostrix® provides significant protection against a B. pertussis challenge (green bar: vaccinated, blue bar:
non-vaccinated), exposure to trypanosomes abrogated vaccine-induced protection (red bar). In humans (lower panel), trypanosome infections were shown to
suppress vaccine induced anti-measles antibodies. Serum antibody titers in vaccinated T. gambiense HAT patients (blue bar) were shown to be significantly lower as
compared to vaccinated control individuals (green bar), and specific antibody titers did not recover after curative anti-HAT treatment (red bar) (121).
T cells (9). However, a most recent effort to understand the full
kinetics of IL-10 production during trypanosomosis, using the
IL-10 reporter mouse system, has indicated that a whole range
of cells is capable of producing IL-10 during infection and that
most notably CD4+ T cells, that do not have a defined regulatory
phenotype, are the main producers of this cytokine (159).
As for the role of IFNγ in parasitaemia control, early reports
characterized this cytokine as a trypanosome growth factor
(160). In contrast, a number of follow-up reports have indicated
that IFNγ is crucial for inhibition of trypanosome growth, as
well as for trypanosomosis-associated NO production and TNF
production that both limit trypanosome growth (152, 161, 162).
Both these factors have subsequently been identified as direct
players in the control of peak parasitaemia levels in T. brucei
as well as T. congolense infections. Using TNF knockout mice,
it was shown that parasitaemia control in relatively resistant
C57Bl/6 mice depends on TNF production during the first peak
of parasitaemia (163, 164). This confirmed initial reports in which
neutralizing anti-TNF antibodies had a negative effect on T.
brucei parasitaemia control (165). Subsequently, a comparative
infection model using BALB/c, C57Bl/6, C3H/HeN, and CBA/Ca
mice showed that while TNF production per se was required
for proper parasitaemia control, infected mice responded to
TNF-associated inflammation with the shedding of TNF-R2
receptors. This, in turn resulted in limiting the TNF-mediated
infection-associated immunopathology (166). Based on these
results, and placing these observations in the wider context
of trypanosome infections using various gene-deficient mouse
models, it has been proposed that while soluble TNF could plays
a pivotal role in parasitaemia control, it is the membrane-bound
form of the cytokine that has a major impact on progressing
inflammation and inducing pathology (167). When analyzing the
possible direct effect of TNF on trypanosomes, results showed a
differential outcome depending upon the model studied. First,
it was reported for the T. brucei brucei AnTat 1.1 clone that
TNF has a direct trypanolytic effect. The latter is mediated by
a lectin binding domain of the TNF molecule that is located at
the opposite site of the molecule as compared to the mammalian
receptor binding site (168). Interestingly, the lectin specificity
of TNF exhibits a high affinity for complex branched mannose
Frontiers in Immunology | www.frontiersin.org 12 October 2018 | Volume 9 | Article 2253
Radwanska et al. Host-Parasite Interactions in Trypanosomosis
sugars, such as those found on the trypanosome VSG molecule
(169). Using a model for T. brucei gambiense, these findings were
independently confirmed in an in vitro co-culture system (170).
In contrast, experimental mouse studies with the human infective
T. brucei rhodesiense LouTat 1 clone did not show a direct
effect of TNF (171), suggesting that various trypanosome stocks
can exhibit different levels of susceptibility to host cytokine-
mediated growth regulation, as might be the case for IFNγ.
Studies in trypanotolerant vs. trypanosusceptible cattle, using
a T. congolense model, confirmed the possible role of TNF in
parasitaemia control in natural infections (172), but here no
link was made to a possible direct trypanolytic effect of the
cytokine. Also, for the T. congolense infection mouse model,
the direct action of TNF has not been reported but here TNF-
R1 signaling has been associated to the combined release of
soluble TNF and NO by activated macrophages. Those two
combined were shown to play a crucial role in parasitaemia
control, in conjunction with infection-induced anti-trypanosome
antibodies (118). Interesting to note here is that in contrast
to the limited knowledge on the molecular mechanisms of
trypanosomosis-driven T cell IFNγ production, detailed research
into themechanisms ofmacrophage-derived TNF induction have
been able to provide a more in-depth understanding of the
host-parasite interplay. Indeed, first the VSG-GPI anchor was
identified as the major trypanosome molecule responsible for
TNF induction, with the trypanosome-specific galactose side-
branch of the anchor playing a major role in macrophage
activation (173, 174). Subsequently, it was shown that IFNγ
could prime macrophages to become responsive to GPI-VSG and
trypanosome stimulation (175). These results are in line with
in vivo data showing that a rise in serum IFNγ values precedes
the induction of infection-associated TNF (154). However, when
macrophages are primed with VSG, prior to IFNγ, the cells
are de-sensitize with respect to cytokine secretion (175). This
may represent a way to prevent hyper-inflammation during the
phase that corresponds to peak parasitaemia clearance, in which
massive amounts of VSG are being released into the hosts’
circulation. This information has been used to try and design
an anti-disease vaccination approach for trypanosomosis (176).
Although it was shown that repeated exposure to VSG-GPI
prior to infection could indeed reduce the infection-associated
pathology related to excessive macrophage activation, the results
indicated that the vaccine approach did not result in the buildup
of immunological memory involving antibodies or B cells.
Instead, the reduction of inflammation, following the repeated
GPI exposure related to an alteration of macrophage phenotypes,
shifted the balance from infection-induced inflammatory type 1
cells to more anti-inflammatory type 2 cells or macrophages. This
response was short-lived. Moreover, as the beneficial effect of the
VSG-GPI treatment was observed to the same extent in both B
cell deficient mice and in wild-type littermates, it became clear
the approach could no longer be considered as a possible vaccine
approach (177). In addition to the VSG-GPI, trypanosome
DNA that contains high levels of unmethylated CpG sequences
has been reported to be responsible for driving NF-κB an
MAPK signaling pathways, resulting in the transcription of
pro-inflammatory cytokine genes including tnf, in case of T.
brucei infection(178). As for infection with T. evansi, the
information on the role of IFNγ is limited, but data has shown
that in addition to anti-trypanosome antibodies, this cytokine
is required for parasitaemia control (179). Most recently, a
comparative cytokine analysis using different T. evansi infections
confirmed the induction of IFNγ in all infections (180). For T.
vivax infections, there is a general lack of published information
on the role of T cells and their cytokines in the control of onset
in infection, but it appears reasonable to assume that a similar
cytokine environment is needed to obtain the best parasitaemia
control possible. As for human (T. b. rhodesiense) and cattle (T.
congolense) infection, the role of IFNγ in inducing inflammatory
pathology has been confirmed in both (181, 182), and as already
outlined above, IFNγ has been shown to play a major role in the
actual cerebral complications that characterize human sleeping
sickness (183).
ANEMIA IS A MAJOR PATHOLOGICAL
FEATURE OF ANIMAL TRYPANOSOMOSIS
From the data reviewed above, it has become clear that
the IFNγ/TNF driven immunopathology is a hallmark of
trypanosomosis in both human and livestock. When focusing
on the latter it has been amply documented that TNF-linked
infection-associated anemia is the major pathological feature
that marks both T. congolense and T. vivax trypanosomosis.
In fact, the classification of so-called trypanotolerant and
trypanosusceptible animals is based on the relative capacity to
control anemia during infection which consequently is directly
linked to whether or not animals remain productive while
infected with trypanosomes (184). Mechanisms that underlie this
tolerance are complex and to date still not clearly understood,
but most likely include differences in erythropoeitic potential
and hemodilution (185), factors involved in erythrolysis (186),
eryhtrophagocytosis (187), the regulation of the erythropoietin
homeostasis (188), the host’s potential to raise neutralizing
antibodies against secreted trypanosome virulence factors (189),
and the general mechanism involved in inflammation control
such as the regulation of the IFNγ/IL-10 balance as well as
other cytokines (167). With respect to cytokine regulation
during infection, it is worth mentioning that MIF (Macrophage
migration Inhibitory Factor) was recently shown to be one of the
key trypanosomosis-associated inflammation inducing cytokines
involved in the promotion of so-called anemia of inflammation,
in which classically activated macrophages also play a major role
(190). Indeed, it was shown that MIF promotes the storage of
iron in liver myeloid cells, subsequently depriving iron from the
eythropoeitic system and preventing the maturation of RBCs.
Important here is that the T. congolense C57Bl/6 mouse model
has been proven useful over the years to unravel the molecular
mechanisms that govern anemia pathology. Gene expression
profiling studies in these mice have pinpointed infection-induced
deregulation of erythropoiesis as well as the involvement of
stress-induced acute phase responses linked to T. congolense-
associated anemia (191). More recently, the C57Bl/6 model was
also shown to be suitable for unraveling the pathology of T.
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vivax infections (129, 192, 193). In addition, the use of various
knockout mouse strains generated on the C56Bl/6 background,
such as TNF−/− and Lymphytoxin−/− (194), TNFp75−/− (166),
IFNγR−/− (152), IL-10−/− (195), and Gal3−/− (196) have
all been used to study specific aspects of the inflammatory
cascade that drive trypanosomosis-associated inflammation. One
of the most recent finding here has shown that the reduced
PCV, associated with experimental mouse trypanosomosis, is
not just the result of reduced circulating RBC numbers, but
also of increased plasma volume, leading to hemodilution. The
reduction of platelet concentrations in T. congolense-infected
mice has also been reported in T. congolense-infected cattle and
sheep (197, 198) suggesting that hemodilution could be a major
pathogenic characteristic of livestock trypanosomosis, as well.
To date, the characteristics of anemia are probably the most
and best described features of AT. Whenever new surveillance
efforts result in the discovery of new infection foci, anemia
is usually the parameter that is used to describe disease
severity. This is the case for T. evansi, T. congolense, and T.
vivax independently of the geographic location of infection
or host species. As described for T. congolense, T. evansi-
induced anemia was linked to infection-associated deregulation
of the iron metabolism as well (199), although the number
of detailed mechanistic studies available for this infection are
rare. Interestingly, trypanosomosis-associated anemia has even
been observed in more rare infection cases of wildlife in the
Australian little red flying fox infected with T. minasense and
T. rangeli (200). Together, all these reports indicate that the
general occurrence of trypanosomosis-associated anemia is most
likely due to the multitude of inflammatory pathways, and
linked to various aspects of impaired RBC development and
clearance. Taken this into account, it is very intriguing that
reports of severe infection-associated anemia are missing in the
case of HAT. Indeed, most reports documenting HAT-associated
anemia describe the induction of RBC lysis and acute anemia
as the result of treatment rather than the infection itself. This
is particularly the case for T. b. gambiense infections (201–204).
For T. b. rhodesiense rare reports do exist on the occurrence
of infection-associated anemia and hemolysis (205), and models
have been developed using vervet monkeys to investigate this
aspect of acute HAT pathology in details (206). However, at the
same time other reports have shown the lack of any correlation
between T. b. rhodesiense severity in humans and the presence
or absence of anemia (207–209). Hence, it seems that the human
immune system might have found unique ways of dealing with
trypanosomosis both in terms of dealing with parasite killing
through the TLF1/2 ApoL1 mechanisms, as well as the control
of infection-associated anemia.
CONCLUSION
Over the past years, international joint efforts to control Human
African Trypanosomosis have resulted in a drastic reduction
in the number of confirmed disease cases. In addition, it
might be feasible that by 2020 the incidence of this neglected
tropic disease will be reduced to levels where it is no longer
considered as a public health threat. However, at the same
time the incidence of animal trypanosomosis is on the rise,
affecting animal productivity through the detrimental health
effects caused by excessive host-parasite immune interactions.
This has now become a world-wide issue that affects agricultural
infrastructures in emerging economy countries, not just in
Africa but also in Asia and South America. In addition, AT
even threatens the livestock industry of developed countries
when sudden outbreaks occur due to importation of the disease
either through infected vectors or host animals. To date, not a
single vaccine strategy is available to control AT. Detrimental
infection-associated mechanisms undermine both T cell and B
cell compartments, making it virtually impossible to develop
methods that allow the generation of long-term sustainable
immunological memory. It appears that in the evolutionary battle
between the trypanosome and the host immune system, the
parasite has not only been able to find ways to evade innate
trypanosome killing mechanisms, but has also acquired tools
to undermine the crucial immunological defense and memory
systems of the host. Only recently, it has become obvious that
one of the major strengths of the African Trypanosomes’ defense
system is the capacity of genetic exchanges between individual
parasites, while residing in the insect vector. Through this
mechanism, new human-infective parasites can be generated
and this by combining resistant genes from existing T. b.
rhodesiense parasites with the vast repertoire of the T. b. brucei
animal parasite reservoir. In addition, it has become clear that
mechanisms of genetic plasticity also have allowed T. b. brucei
to transform into T. equiperdum and T. evansi, parasites that
have now successfully conquered large areas of the developing
world, as they no longer need the tsetse vector for transmission.
In particular, the latter risks to become a future health problem,
as human infective cases of T. evansi have already been reported
in India, Vietnam, Egypt, and Algeria. Together, these results
show that while classic T. gambiense trypanosomosis is becoming
rare, AT and new atypical human trypanosomosis remain a
serious risk for the human population. Future research into
the host-parasite interactions and trypanosomosis- associated
inflammation of these new atypical infections should allow to
obtain a better understanding of problems, including vaccine
failure, and hopefully lead us to a long-term solution that can
deal with both human and livestock infections, as well as the ever
surviving wildlife trypanosome reservoir.
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